Coger: Distributeur de reactifs de laboratoire
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
|
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
|
Stock épuisé.
En rupture de stock
|
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
Delanzomib [CEP-18770]
5 mg
photos non contractuelles
Détails Produit
Product description: Potent, selective, reversible orally bioavailable proteasome inhibitor. Synthetic P2 threonine boronic acid. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.8nM). Cross-reacts and inhibits the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=~70nM). Displays similar potency for the chymotrypsin-like activity of the proteasome compared to bortezomib. Exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors and bone marrow-derived stromal cells relative to bortezomib (Prod. No. AG-CR1-3602). Anticancer compound effective against multiple myeloma in vivo. In vitro, blocks the growth of representative human solid and hematological tumor cell lines (IC50s=5.6-34nM). Shown to down-modulate NF-kappaB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.
Alternate Names/Synonyms: NPH 007098; CT 47098; CIP 18770; [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
CAS: 847499-27-8
|
Alerte
Veuillez saisir les champs obligatoires! |
